The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial

PloS One
André Maurício S FernandesRoque Aras Junior

Abstract

Studies have demonstrated that phosphodiesterase 5 (PDE5) inhibition is associated with right ventricle (RV) functional improvement in patients with primary pulmonary hypertension. This study aims to demonstrate the immediate impact of Sildenafil, a PDE5 inhibitor, on RV function, measured by cardiovascular magnetic resonance (CMR), in patients with heart failure (HF). We conducted a randomized double-blind controlled trial. diagnosis of HF functional class I-III; left ventricle ejection fraction < 35%. Patients underwent CMR evaluation and were then equally randomly assigned to either 50 mg of Sildenafil or Placebo groups. One hour following drug administration, they were submitted to a second scan examination. 26 patients were recruited from a tertiary reference center in Brazil and 13 were allocated to each study group. The median age was 61.5 years (50-66.5 years). Except for the increase in RV fractional area change following the administration of sildenafil (Sildenafil [before vs. after]: 34.3 [25.2-43.6]% vs. 42.9 [28.5-46.7]%, p = 0.04; Placebo [before vs. after]: 28.1 [9.2-34.8]% vs. 29.2 [22.5-38.8]%, p = 0.86), there was no statistically significant change in parameters. There was no improvement in left ventricular p...Continue Reading

Associated Clinical Trials

References

Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
May 9, 2007·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Aasha S GopalNathaniel Reichek
Jan 29, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Fadi N SalloumRakesh C Kukreja
Nov 14, 2008·European Journal of Heart Failure·Asger AndersenJens Erik Nielsen-Kudsk
Jun 8, 2010·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·Taco KindAnton Vonk-Noordegraaf
Aug 31, 2011·Progress in Cardiovascular Diseases·Francois HaddadVinicio de Jesus Perez
Nov 23, 2011·International Journal of Cardiology·Daniel DumitrescuStephan Rosenkranz
Dec 3, 2011·Circulation. Heart Failure·Xiaoyin ShanKenneth B Margulies
Jun 26, 2012·European Journal of Heart Failure·Marinus A J BorgdorffRolf M F Berger

❮ Previous
Next ❯

Citations

Nov 14, 2019·British Journal of Pharmacology·Nikolaos TzoumasDavid J Webb
Dec 14, 2018·Expert Opinion on Investigational Drugs·Juan TamargoEva Delpón

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01936350

Software Mentioned

ARGUS 4D VF

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.